All In Biotech

Drug Trial Radar · NCT01163032

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon Versus Placebo in Totally Blind Subjects With N24HSWD Followed by an OLE Phase

Last checked: Nov 19, 2026Latest source record: Oct 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Aug 2010

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder

Conditions

  • Non-24-Hour Sleep-Wake Disorder

Interventions

  • tasimelteonDrug

    20 mg tasimelteon capsules, PO daily for 6 months

  • PlaceboDrug

    Placebo capsules, PO daily for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Entrained as Assessed by Urinary aMT6Time frame: 1 month
  2. Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of ≥ 3 on N24CRSTime frame: 6 months

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • Pulmonary Associates, PA

    Phoenix, Arizona

  • SDS Clinical Trials Inc.

    Orange, California

  • VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)

    Palo Alto, California

  • St. Johns Sleep Disorder Center - St. Johns Medical Plaza

    Santa Monica, California

  • Radiant Research - Denver

    Denver, Colorado

  • PAB Clinical Research Inc.

    Brandon, Florida

  • Kendall South Medical Center, Inc.

    Miami, Florida

  • Ocean Sleep Disorders Center - Ormond Beach

    Ormond Beach, Florida

  • Sleep Disorders Center Of Georgia

    Atlanta, Georgia

  • Suburban Lung Associates SC (Chicago Metropolitan Area)

    Elk Grove Village, Illinois

  • The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)

    Chevy Chase, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Michigan Head-Pain Neurological Institute

    Ann Arbor, Michigan

  • St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)

    Chesterfield, Missouri

  • New York Eye and Ear Infirmary

    New York, New York

  • Tri-State Sleep Disorders Center

    Cincinnati, Ohio

  • Ohio Sleep Medicine Institute (Columbus Metropolitan Area)

    Dublin, Ohio

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Columbia Research Group Inc.

    Portland, Oregon

  • Center For Sleep Medicine at Chestnut Hill Hospital

    Philadelphia, Pennsylvania

  • Consolidated Clinical trials

    Pittsburgh, Pennsylvania

  • SleepMed, Inc. - Columbia

    Columbia, South Carolina

  • Todd J. Swick, M.D., P.A.

    Houston, Texas

  • Advanced Sleep Research GmbH

    Berlin, Germany

  • Bergmannsheil University Hospital - Medical Clinic III

    Bochum, Germany

  • Klinische-Forschung Hannover Mitte

    Hanover, Germany

  • Universitaetsklinikum Glesen and Marburg gmbH/Schlaflabor - Sleep Lab University Marburg

    Marburg, Germany

  • Bonomed Studiezentrum

    Munich, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.